Cash from Operations (Quarterly) Chart

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2017. Start Trial.
Date Value
June 30, 2026 -38.54M
March 31, 2026 17.81M
December 31, 2025 46.63M
September 30, 2025 -12.22M
June 30, 2025 -43.95M
March 31, 2025 -36.83M
December 31, 2024 -23.28M
September 30, 2024 -25.02M
June 30, 2024 -19.46M
March 31, 2024 -36.74M
December 31, 2023 -14.55M
September 30, 2023 -24.41M
June 30, 2023 -29.01M
March 31, 2023 -37.39M
December 31, 2022
September 30, 2022 -20.73M
June 30, 2022 -27.81M
March 31, 2022 -8.298M
December 31, 2021 18.83M
Date Value
September 30, 2021 -17.18M
June 30, 2021 -21.26M
March 31, 2021 9.086M
December 31, 2020 -29.56M
September 30, 2020 -9.142M
June 30, 2020 -12.88M
March 31, 2020 -12.38M
December 31, 2019 -21.97M
September 30, 2019 -18.41M
June 30, 2019 -21.74M
March 31, 2019 82.17M
December 31, 2018 -11.47M
September 30, 2018 -10.99M
June 30, 2018 -19.03M
March 31, 2018 -17.40M
December 31, 2017
September 30, 2017 -3.815M
June 30, 2017 -4.135M
March 31, 2017 -6.395M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Xencor, Inc. -55.66M
UroGen Pharma Ltd. -35.02M
Ironwood Pharmaceuticals, Inc. 58.28M
Viking Therapeutics, Inc. -125.17M
IDEAYA Biosciences, Inc. -88.21M